CPRC
MRK icon

Consolidated Portfolio Review Corp’s Merck MRK Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,924
Closed -$413K – 262
2025
Q3 		$413K Buy
4,924
+70
+1% +$5.77K 0.05% 300
2025
Q2 		$384K Buy
4,854
+72
+2% +$5.72K 0.05% 298
2025
Q1 		$429K Buy
4,782
+67
+1% +$6.26K 0.07% 245
2024
Q4 		$469K Buy
4,715
+773
+20% +$79.7K 0.07% 234
2024
Q3 		$448K Sell
3,942
-219
-5% -$26K 0.1% 195
2024
Q2 		$515K Buy
4,161
+346
+9% +$44.6K 0.12% 177
2024
Q1 		$503K Sell
3,815
-40
-1% -$4.93K 0.13% 161
2023
Q4 		$420K Sell
3,855
-596
-13% -$61.9K 0.1% 189
2023
Q3 		$458K Buy
4,451
+154
+4% +$16.6K 0.11% 176
2023
Q2 		$496K Sell
4,297
-71
-2% -$8.06K 0.12% 164
2023
Q1 		$465K Buy
+4,368
New +$472K 0.13% 162

Other funds holding MRK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Consolidated Portfolio Review Corp's MRK Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Merck (MRK) in Q4 2025, closing a stake of 4,924 shares — an estimated $413K sold.

Consolidated Portfolio Review Corp first reported a position in MRK in Q1 2023 and held it in 11 quarters. The position peaked at $515K in Q2 2024. 3,654 funds tracked by Wall St. Rank hold MRK as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining Merck position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 4,924 Merck shares in Q4 2025, an estimated $413K.
  • Consolidated Portfolio Review Corp first reported a position in Merck in Q1 2023 and held it in 11 quarters.
  • Consolidated Portfolio Review Corp's Merck position peaked at $515K in Q2 2024.
  • 3,654 funds tracked by Wall St. Rank held Merck as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.